Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

J Natl Compr Canc Netw. 2018 Oct;16(10):1216-1247. doi: 10.6004/jnccn.2018.0078.

Abstract

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common physical and psychosocial consequences of cancer and cancer treatment to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period. This portion of the guidelines describes recommendations regarding the management of anthracycline-induced cardiotoxicity and lymphedema. In addition, recommendations regarding immunizations and the prevention of infections in cancer survivors are included.

MeSH terms

  • Anthracyclines / adverse effects
  • Antibiotics, Antineoplastic / adverse effects
  • Antineoplastic Agents, Immunological / adverse effects
  • Bacterial Infections / immunology
  • Bacterial Infections / prevention & control
  • Cancer Survivors*
  • Cardiotoxicity / diagnosis
  • Cardiotoxicity / etiology
  • Cardiotoxicity / therapy
  • Humans
  • Immunocompromised Host / drug effects
  • Immunocompromised Host / immunology
  • Immunocompromised Host / radiation effects
  • Lymphedema / chemically induced
  • Lymphedema / diagnosis
  • Lymphedema / therapy
  • Mass Screening / methods
  • Mass Screening / standards
  • Medical Oncology / methods
  • Medical Oncology / standards*
  • Neoplasms / complications
  • Neoplasms / immunology
  • Neoplasms / psychology
  • Neoplasms / therapy*
  • Risk Assessment / methods
  • Risk Assessment / standards
  • Societies, Medical / standards
  • Survivorship*
  • United States
  • Vaccination / methods
  • Vaccination / standards
  • Virus Diseases / immunology
  • Virus Diseases / prevention & control

Substances

  • Anthracyclines
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents, Immunological